Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
18 hedge funds and large institutions have $20.5M invested in Soleno Therapeutics in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
6% more funds holding
Funds holding: 17 → 18 (+1)
0.23% less ownership
Funds ownership: 3.2% → 2.96% (-0.23%)
7% less capital invested
Capital invested by funds: $22.2M → $20.5M (-$1.64M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$70.3K |
| 2 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
+$57.2K |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$52.3K |
| 4 |
SAM
Shikiar Asset Management
New York
|
+$49.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$74.2K |
| 2 |
BC
Birchview Capital
Burlington,
Vermont
|
-$52.9K |
| 3 |
VF
Virtu Financial
New York
|
-$42K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$30K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$13.5K |
SLNO Hedge Fund Activity: Q3 2018 in Review
18 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2018, worth a combined $20.5M — down 7.4% from $22.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SLNO positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $70.3K. The largest seller was Sabby Management, cutting an estimated $74.2K.
- 18 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2018, up from 17 in Q2 2018.
- Funds reported $20.5M of Soleno Therapeutics stock for Q3 2018, down 7.4% quarter-over-quarter.
- 4 funds opened new Soleno Therapeutics positions in Q3 2018 and 3 closed out, a net change of +1 holder.
- The largest Soleno Therapeutics buyer in Q3 2018 was Geode Capital Management, an estimated $70.3K added.
- The largest Soleno Therapeutics seller in Q3 2018 was Sabby Management, an estimated $74.2K sold.
Based on aggregated 13F filings for Q3 2018.